CC
MDGL icon

Corton Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Corton Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-695
Closed -$210K – 320
2025
Q2 		$210K Buy
+695
New +$207K 0.24% 220
2022
Q2 		– Sell
-2,108
Closed -$207K – 442
2022
Q1 		$207K Buy
+2,108
New +$178K 0.09% 352

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Corton Capital's MDGL Position: Q3 2025 in Review

Corton Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 695 shares — an estimated $210K sold.

Corton Capital first reported a position in MDGL in Q1 2022 and held it in 2 quarters. The position peaked at $210K in Q2 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Corton Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Corton Capital sold 695 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $210K.
  • Corton Capital first reported a position in Madrigal Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Corton Capital's Madrigal Pharmaceuticals position peaked at $210K in Q2 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.